In 2021, sacituzumab govitecan, an anti–Trop-2 antibody–drug conjugate, received US Food and Drug Administration approval for the treatment of patients with locally advanced or metastatic TNBC who have received ≥2 prior systemic therapies, including ≥1 therapy for metastatic disease (40). The gene discussed is TACSTD2; the disease is metastatic neoplasm.